Tandem Investment Advisors Inc. reduced its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 14.4% in the 1st quarter, Holdings Channel reports. The firm owned 232,179 shares of the medical technology company’s stock after selling 39,189 shares during the period. Stryker accounts for approximately 3.7% of Tandem Investment Advisors Inc.’s holdings, making the stock its 11th largest position. Tandem Investment Advisors Inc.’s holdings in Stryker were worth $76,292,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of SYK. Sankala Group LLC bought a new position in shares of Stryker in the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker in the fourth quarter valued at about $27,000. Finally, DJE Kapital AG acquired a new stake in Stryker in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have commented on SYK shares. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Truist Financial reaffirmed a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Canaccord Genuity Group lowered their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.
More Stryker News
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
- Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
- Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
- Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
- Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
- Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)
Stryker Price Performance
Shares of SYK opened at $319.78 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The business has a 50-day simple moving average of $312.69 and a two-hundred day simple moving average of $336.82. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The stock has a market cap of $122.59 billion, a PE ratio of 37.01, a PEG ratio of 2.05 and a beta of 0.77.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts anticipate that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.
Insider Buying and Selling at Stryker
In related news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by company insiders.
About Stryker
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Further Reading
- Five stocks we like better than Stryker
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
